103 related articles for article (PubMed ID: 24322416)
1. [A case of testicular tumor of ovarian epithelial type].
Nishimoto M; Shimizu N; Kikuchi T; Kobayashi Y; Yamamoto Y; Minami T; Hayashi T; Tsuji H; Nozawa M; Yoshimura K; Ishii T; Uemura H
Hinyokika Kiyo; 2013 Nov; 59(11):753-7. PubMed ID: 24322416
[TBL] [Abstract][Full Text] [Related]
2. Seromucinous borderline tumor of the testis-A case report.
Scholz B; Beckert M; Mordstein V; Hohmann N; Walther R; Papadopoulos T
Hum Pathol; 2017 Feb; 60():188-191. PubMed ID: 27597522
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of combined PET/CT for patient with epithelial ovarian cancer showing recurrence based on tumor marker CA125.
Muramatsu T; Yamashita E; Takahashi K; Sugiyama T; Tsukada H; Kondo A; Hirasawa T; Murakami M; Yasuda S; Mikami M
Tokai J Exp Clin Med; 2007 Mar; 32(1):23-7. PubMed ID: 21319052
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
Hainsworth JD; Thompson DS; Bismayer JA; Gian VG; Merritt WM; Whorf RC; Finney LH; Dudley BS
Cancer Med; 2015 May; 4(5):673-81. PubMed ID: 25556916
[TBL] [Abstract][Full Text] [Related]
5. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
6. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
Guo N; Peng Z
J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
[TBL] [Abstract][Full Text] [Related]
7. Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.
Nguyen TM; Shin IW; Lee TJ; Park J; Kim JH; Park MS; Lee EJ
Gynecol Oncol; 2016 Mar; 140(3):545-53. PubMed ID: 26691219
[TBL] [Abstract][Full Text] [Related]
8. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
9. Ovarian-type epithelial tumour of borderline malignancy: a rare testicular tumour in Australia.
Rutagengwa D; Rathore P; Morris E
ANZ J Surg; 2019 Dec; 89(12):1676-1677. PubMed ID: 30239110
[No Abstract] [Full Text] [Related]
10. Chemosensitivity of malignant ovarian-type surface epithelial tumor of testis.
Vaughn DJ; Rizzo TA; Malkowicz SB
Urology; 2005 Sep; 66(3):658. PubMed ID: 16140110
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K;
Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349
[TBL] [Abstract][Full Text] [Related]
12. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.
Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F
Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814
[TBL] [Abstract][Full Text] [Related]
13. Very late recurrence (after more than 20 years) of epithelial ovarian carcinoma: case report and literature review.
Menczer J; Schreiber L; Peled O; Levy T
Arch Gynecol Obstet; 2015 Jun; 291(6):1199-203. PubMed ID: 25524538
[TBL] [Abstract][Full Text] [Related]
14. iCTC drug resistance (CDR) Testing ex vivo for evaluation of available therapies to treat patients with epithelial ovarian cancer.
Pearl ML; Dong H; Zhao Q; Tulley S; Dombroff MK; Chen WT
Gynecol Oncol; 2017 Nov; 147(2):426-432. PubMed ID: 28830645
[TBL] [Abstract][Full Text] [Related]
15. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
16. A brief history of the pathology of the gonads.
Young RH
Mod Pathol; 2005 Feb; 18 Suppl 2():S3-S17. PubMed ID: 15529187
[TBL] [Abstract][Full Text] [Related]
17. Co-Existing Ovarian Mucinous Cystadenocarcinoma with Mature Cystic Teratoma: A Rare Case Report.
Suwannarurk K; Thaweekul Y; Mairaing K; Poomtavorn Y; Piyawong W; Himakhun W; Bhamarapravatana K
J Med Assoc Thai; 2016 Jul; 99 Suppl 4():S281-6. PubMed ID: 29927186
[TBL] [Abstract][Full Text] [Related]
18. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity.
Mann JR; Raafat F; Robinson K; Imeson J; Gornall P; Sokal M; Gray E; McKeever P; Hale J; Bailey S; Oakhill A
J Clin Oncol; 2000 Nov; 18(22):3809-18. PubMed ID: 11078494
[TBL] [Abstract][Full Text] [Related]
19. [Infertility and testicular seminoma].
Lakmichi MA; Niang L; Tligui M; Traxer O; Cussenot O; Gattegno B; Thibault P; Sebe P
Presse Med; 2007 Dec; 36(12 Pt 1):1753-5. PubMed ID: 17560758
[TBL] [Abstract][Full Text] [Related]
20. Does Human Epididymis Protein 4 (HE4) Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer.
Innao P; Pothisuwan M; Pengsa P
Asian Pac J Cancer Prev; 2016; 17(9):4483-4486. PubMed ID: 27797265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
